Johnson & Johnson down to its final Zytiga defenses as judge puts temporary kibosh on generics

courthouse
Johnson & Johnson lost patent protections for blockbuster prostate cancer drug Zytiga, potentially enabling generics to launch this week. (Pixabay)

Zytiga copycats may be revving up for launches later this week, thanks to a brand-new patent ruling. But Johnson & Johnson isn't giving up the fight for its prostate cancer blockbuster—and the 71% growth it has turned in so far this year.

U.S. District Judge Kevin McNulty on Friday invalidated a key patent protecting Zytiga, one of the leading prostate cancer therapies on the market. But as J&J made clear it wasn't giving up the fight, McNulty also ordered generics makers to hold off on their launches until at least Wednesday.

In a statement, the company said it “strongly disagrees” with the ruling, and it is asking the court for an injunction against those launches until its appeal can be heard.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Zytiga has been driving growth for J&J ever since its launch back in 2011 took off faster than pharma watchers expected, and even now, its sales are leaping ahead. Propelled by strong data and a label expansion to treat metastatic high-risk castration-sensitive prostate cancer, Zytiga generated $1.42 billion in the U.S. in the first nine months of 2018, a 71% boost year over year.

But as generic competition looms, J&J executives insist they don't need Zytiga to keep sales growth coming. On the company’s third-quarter conference call, they said the company has a broad pharma portfolio that turned in 8.2% growth excluding currency effects; without Zytiga, the unit still grew by 6.6%.

RELATED: Johnson & Johnson would be just fine without Zytiga, executives insist as patent decision looms 

Plus, Zytiga's international growth can help soften the blow. Internationally, the drug posted sales of $1.29 billion through the first nine months of this year, a 40% increase, and Zytiga boasts patent protections in Europe until 2027, J&J said.

Meanwhile, J&J has pinned new hopes on its follow-up prostate cancer drug Erleada. But cheap Zytiga generics could undercut that drug and another rival in the disease area, Pfizer's Xtandi. J&J hasn't yet released sales figures for Erleada.

RELATED: J&J's blockbuster Zytiga falls to patent challenge, boosting threat of 2018 generics 

The latest ruling followed another loss for Zytiga at the start of this year, when the U.S. Patent Trial and Appeals Board invalidated a patent on the drug. At the time, an analyst wrote that he expected Zytiga generics to make their debut this month, after the expiration of a 30-month stay mandated by the Hatch-Waxman Act.

Amneal and Wockhardt have tentative FDA approvals for their generics, according to the FDA's website.

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.